Patents by Inventor Alexei Tulin

Alexei Tulin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Poly(ADP-ribose) polymerase 1 inhibitors structurally unrelated to NAD
    Patent number: 10550108
    Abstract: Compounds that are not related to NAD, and which target PARP1-histone H4 interaction are provided, as well as compositions of these compounds, and methods for specific inhibition of poly(ADP-ribose) polymerase 1 (PARP-1) using these compounds are provided. These PARP-1 inhibitors may be used to treat cancer in which PARP-1 activation or biologic activity plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: February 4, 2020
    Assignee: Institute For Cancer Research
    Inventor: Alexei Tulin
  • Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors
    Patent number: 10472664
    Abstract: Screening methods as well as systems and kits for identifying inhibitors of DNA-independent, histone H4-dependent activation of PARP-1 are provided. The methods comprise screening molecules for their capacity to inhibit the activation and/or biologic activity of PARP-1, as measured by poly(ADP)-ribose production from nicotinamide adenine dinucleotide. PARP-1 inhibitors identified through the screening methods may be used to treat cancer in which PARP-1 activation or biologic activity plays a role.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: November 12, 2019
    Assignee: Institute For Cancer Research
    Inventor: Alexei Tulin
  • Poly(ADP-Ribose) Polymerase 1 Inhibitors Structurally Unrelated to NAD
    Publication number: 20170283402
    Abstract: Compounds that are not related to NAD, and which target PARP1-histone H4 interaction are provided, as well as compositions of these compounds, and methods for specific inhibition of poly(ADP-ribose) polymerase 1 (PARP-1) using these compounds are provided. These PARP-1 inhibitors may be used to treat cancer in which PARP-1 activation or biologic activity plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Application
    Filed: September 30, 2015
    Publication date: October 5, 2017
    Inventor: Alexei Tulin
  • SCREENING ASSAY FOR IDENTIFICATION OF POLY(ADP-RIBOSE) POLYMERASE 1 INHIBITORS
    Publication number: 20160097083
    Abstract: Screening methods as well as systems and kits for identifying inhibitors of DNA-independent, histone H4-dependent activation of PARP-1 are provided. The methods comprise screening molecules for their capacity to inhibit the activation and/or biologic activity of PARP-1, as measured by poly(ADP)-ribose production from nicotinamide adenine dinucleotide. PARP-1 inhibitors identified through the screening methods may be used to treat cancer in which PARP-1 activation or biologic activity plays a role.
    Type: Application
    Filed: September 30, 2015
    Publication date: April 7, 2016
    Inventor: Alexei Tulin